Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)

NCT06071377 · View on ClinicalTrials.gov ↗

Study Summary

The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.

Conditions Studied

Interventions

  • OTHER Biologic Specimen Collection

Study Locations (10)

North Carolina

  • University of North Carolina — Chapel Hill
  • Duke University — Durham
  • East Carolina University — Greenville

Alabama

  • University of Alabama — Birmingham

California

  • Loma Linda University Health Care — Loma Linda

Delaware

  • Nemours Children's Hospital — Wilmington

Indiana

  • Indiana University — Indianapolis

Michigan

  • Functional Fluidics — Detroit

Ohio

  • Nationwide Children's Hospital — Columbus

Texas

  • UT Health Houston — Houston

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-04-01
Est. Completion 2027-02

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06071377

The ClinicalTrials.gov registry entry for NCT06071377 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Alliance for Sickle Cell Centers, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Sickle Cell Trait appearing as the primary indexed condition, and to 1 intervention — of which Biologic Specimen Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06071377 reports 10 study locations spanning 8 distinct geographic areas — top geographies include North Carolina, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06071377 about?

NCT06071377 is a clinical study titled "Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)". The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.

What is the current status of trial NCT06071377?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-04-01. Estimated completion is 2027-02.

What conditions does trial NCT06071377 study?

This clinical trial studies the following conditions: Sickle Cell Trait. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06071377?

The interventions under investigation include: Biologic Specimen Collection (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06071377?

This trial is sponsored by National Alliance for Sickle Cell Centers, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06071377 being conducted?

This trial has 10 study locations across Alabama, California, Delaware, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial